Sfoglia per AUTORE
SOLà E
Collezione AOU Città della Salute di Torino

  

Items : 6

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial. in JAMA / JAMA. 2025 Mar 11;333(10):864-874. doi: 10.1001/jama.2024.27441.
2025
AOU Città della Salute di Torino

Pose E; Jiménez C; Zaccherini G; Campion D; Piano S; Uschner FE; de Wit K; Roux O; Gananandan K; Laleman W; Solé C; Alonso S; Cuyàs B; Ariza X; Juanola A; Ma AT; Napoleone L; Gratacós-Ginès J; Tonon M; Pompili E; Sánchez-Delgado J; Allegretti AS; Morales-Ruiz M; Carol M; Pérez-Guasch M; Fabrellas N; Pich J; Martell C; Joyera M; et alii...

Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. in Gut / Gut. 2023 Dec 7;73(1):156-165. doi: 10.1136/gutjnl-2023-329923.
2023
AOU Città della Salute di Torino

Juanola A; Ma AT; de Wit K; Gananandan K; Roux O; Zaccherini G; Jiménez C; Tonon M; Solé C; Villaseca C; Uschner FE; Graupera I; Pose E; Moreta MJ; Campion D; Beuers U; Mookerjee RP; Francoz C; Durand F; Vargas V; Piano S; Alonso S; Trebicka J; Laleman W; Asrani SK; Soriano G; Alessandria C; Serra-Burriel M; Morales-Ruiz M; et alii...

Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. in Journal of hepatology / J Hepatol. 2022 Jan;76(1):107-114. doi: 10.1016/j.jhep.2021.08.031. Epub 2021 Sep 13.
2022
AOU Città della Salute di Torino

Crespo G; Solà E; Torres F; Morales-Ruiz M; Jiménez W; Pose E; Fabrellas N; Ma AT; Avitabile E; Napoleone L; Cervera M; Rubio AB; Escudé L; Bassegoda O; Pérez-Guasch M; Carol M; Solé C; Piano S; Elia C; Juanola A; Graupera I; Ginès P;

The Use of Rifaximin in Patients With Cirrhosis. in Hepatology (Baltimore, Md.) / Hepatology. 2021 Sep;74(3):1660-1673. doi: 10.1002/hep.31708. Epub 2021 Jun 7.
2021
AOU Città della Salute di Torino

Bajaj JS; Krag A; Pose E; Mookerjee RP; Durand F; Angeli P; Trebicka J; de Wit K; Alessandria C; Solà E; Vargas V; Caraceni P; Beuers U; Ginès P;

Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. in Journal of hepatology / J Hepatol. 2021 Jan;74(1):200-219. doi: 10.1016/j.jhep.2020.08.009. Epub 2020 Sep 5.
2021
AOU Città della Salute di Torino

Korenjak M; Watson H; Hernaez R; Krag A; Torres F; Montagnese S; Serra M; Vargas V; Trebicka J; Mookerjee RP; Francoz C; Caraceni P; Beuers U; Alessandria C; Zaccherini G; de Wit K; Uschner F; Piano S; Roux O; Simon-Talero M; Campion D; Pose E; Solà E; Abraldes JG; Kamath PS; Ginès P;

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. in The lancet. Gastroenterology & hepatology / Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31-41. doi: 10.1016/S2468-1253(19)30320-6. Epub 2019 Oct
2020
AOU Città della Salute di Torino

Kamath PS; Abraldes JG; Llopis M; Torres F; Ferrero J; Domenech G; Pich J; Carol M; Andrade RJ; Vargas V; Trebicka J; Mookerjee RP; Durand F; Caraceni P; Bernardi M; Beuers U; Alessandria C; Angeli P; Zaccherini G; de Wit K; Uschner FE; Roux O; Piano S; Jimenez C; Campion D; Amin A; Napoleone L; Pose E; Solà E; et alii...